Home » Topics » Regulatory » EMA

EMA
RSS

Microdosing/phase 0 trials: Paradigm shift aims to speed new drug development, improve efficiency

Nov. 7, 2006

Aldara recommended for approval for actinic keratosis in Europe

Oct. 23, 2006

Positive opinion handed down in Europe for new Glivec indication

Oct. 23, 2006

Europe's CHMP recommends Hycamtin for new indication

Oct. 23, 2006

Tandemact recommended for approval in E.U.

Oct. 23, 2006

European CHMP issues positive opinion on Diacomit submission

Oct. 23, 2006

Adrovance recommended for approval in E.U.

Oct. 23, 2006

Novo Nordisk withdraws E.U. application to expand repaglinide product labels

Oct. 18, 2006

Withdrawal of E.U. marketing authorization for Fortovase

Aug. 14, 2006

Negative opinion handed down for Valdoxan/Thymanax in Europe

Aug. 3, 2006

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...